TSX · BLCO.TO
Bausch + Lomb Corporation
CA$28.75+CA$0.19 (+0.67%)
Bausch + Lomb Corporation’s quoted price sits in the upper half of its reported 52-week range, 3.3% below the high.
Loading market information…
CNQ · DTC.CN · CAD
Stock price, earnings
Quote as of Oct 29, 2026, 06:49 PM UTC. Cached market data; not a live quote.
One-year closing-price history · CAD. Historical prices are not a forecast.
Defence Therapeutics Inc.’s quoted price sits in the lower half of its reported 52-week range, 62.37% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Defence Therapeutics Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Headquartered in Vancouver, Canada, Defence Therapeutics Inc. is a biotechnology company founded in 2017. This firm focuses on pioneering biological and biosimilar therapeutic solutions for both cancer and infectious diseases. A cornerstone of its approach is the exclusive ACCUM™ technology, engineered to precisely and safely transport vaccine antigens or antibody-drug conjugates (ADCs) directly to their intended cellular targets. The company's development efforts span several key areas: novel dendritic cell vaccines for various cancers, protein-based vaccines addressing COVID-19 and other infectious ailments, and specialized antibody-drug conjugate products aimed at different cancer types. Defence Therapeutics Inc. adopted its current name in March 2020, having previously operated as Accum Therapeutics Inc.
Latest available per-share figures in CAD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 07:56 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
CA$28.75+CA$0.19 (+0.67%)
Bausch + Lomb Corporation’s quoted price sits in the upper half of its reported 52-week range, 3.3% below the high.
CA$33.67+CA$0.85 (+2.59%)
Apotex Health Corp.’s quoted price sits in the upper half of its reported 52-week range, 16.2% below the high.
$13.08-$0.56 (-4.11%)
AbCellera Biologics Inc.’s quoted price sits in the upper half of its reported 52-week range, 12.92% below the high.
CA$0.99CA$0.00 (0.0%)
Helix BioPharma Corp.’s quoted price sits in the lower half of its reported 52-week range, 61.92% below the high.
CA$4.65-CA$0.21 (-4.32%)
BriaCell Therapeutics Corp.’s quoted price sits in the lower half of its reported 52-week range, 74.17% below the high.
CA$0.48+CA$0.03 (+5.49%)
Medicenna Therapeutics Corp.’s quoted price sits in the lower half of its reported 52-week range, 73.03% below the high.
CA$0.27-CA$0.01 (-3.57%)
Onco-Innovations Limited’s quoted price sits in the lower half of its reported 52-week range, 85.25% below the high.
CA$0.19+CA$0.02 (+8.57%)
Rakovina Therapeutics Inc’s quoted price sits in the lower half of its reported 52-week range, 40.63% below the high.
